About Synaffix
Synaffix is a company based in Nijmegen (Netherlands) founded in 2010 was acquired by Lonza in June 2023. It operates as a Licensing Model. Synaffix offers products and services including GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads. Synaffix operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Regeneron Pharmaceuticals, Erasca and Revolution Medicines, among others.
- Headquarter Nijmegen, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synaffix B.V.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Synaffix
Synaffix offers a comprehensive portfolio of products and services, including GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads.
Technology for antibody-drug conjugate development is provided.
Spacer technology for enhanced ADC efficacy is offered.
Linker-payloads for targeted cancer therapies are developed.
People of Synaffix
Unlock access to complete
Funding Insights of Synaffix
Investors in Synaffix
Synaffix has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lonza, BOM and BioGeneration Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science focused VC firm investing in startups in Europe
|
Locked | Locked | Locked | |
|
Investments are directed by BOM toward early and growth-stage firms.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in multiple sectors
|
Locked | Locked | Locked |
Investor details for Synaffix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synaffix
Investment portfolio details for Synaffix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Synaffix
Detailed financials for Synaffix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synaffix Comparisons
Peer comparison for Synaffix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synaffix
Synaffix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Regeneron Pharmaceuticals, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Synaffix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synaffix
Complete news archive for Synaffix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synaffix
Synaffix was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Synaffix is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Synaffix is engaged in the development of clinical-stage platform technologies for antibody-drug conjugates (ADCs) and bispecifics, primarily targeting cancer therapeutics. The companys proprietary solutions, including GlycoConnect, HydraSpace, and toxSYN linker-payloads, are designed to enable best-in-class targeted therapies. Operating under a technology out-licensing model, Synaffix collaborates with multiple partners to advance therapeutic candidates across preclinical and clinical phases. The focus is centered on the healthcare sector, specifically biotechnology, with an emphasis on innovative cancer treatment solutions.
Synaffix's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Synaffix offers GlycoConnect®, HydraSpace®, and toxSYN® Linker-Payloads.
Synaffix has 5 investors. Key investors include Lonza, BOM, BioGeneration Ventures, M-Ventures, and Aravis.